grantor: University of TorontoThe ras/erk pathway is a signaling cascade important in cell growth and motility and, consequently, deregulation of this pathway results in human malignancies including several types of cancer. RHAMMv4 is a key regulator of the ras pathway and enhances erk activation in murine fibroblasts. ' In vitro' studies have previously shown that microtubule (MT)-associated proteins (MAPs) and MT catastrophe factors are potential cytoplasmic targets of erk. Erk-mediated phosphorylation of MAPs has been reported to reduce their ability to stabilize MTs 'in vitro'. Here we show that erk, activated by the ras/MEK pathway, decreases MT stability 'in vivo', as detected by a decrease in acetylated Ã-tubulin levels, a ...
We show that expression of the microtubule depolymerizing kinesin KIF2C is induced by transformation...
Receptor for hyaluronan mediated motility (RHAMM, encoded by HMMR) may be a cell-surface receptor fo...
Oncogenic Ras genes are activated by point mutation in about 30% of human tumours, being one of the ...
AbstractIncreasing evidence suggests that activated erk regulates cell functions, at least in part, ...
Increasing evidence suggests that activated erk regulates cell functions, at least in part, by mecha...
An oncogenic form of RHAMM (receptor for hyaluronan-mediated motility, mouse, amino acids 163-794 te...
grantor: University of TorontoWe assessed CD44, RHAMM, erk, and ras expression in human br...
We have previously reported that non-muscle myosin II (NMMII) and myosin light chain kinase (MLCK) a...
AIM: Most neoplastic cells express diminished levels of tropomyosin (TM) family of actin-binding pro...
Activating mutations in the RasGTPases are the most common oncogenic lesions in human cancer. Simila...
Activating mutations in the RasGTPases are the most common oncogenic lesions in human cancer. Simila...
Ras is a key regulator of the MAP kinase-signaling cascade and may cause morphologic change of Ras-t...
This article is hosted on a website external to the CBCRA Open Access Archive. Selecting “View/Open...
Oncogenic transformation often leads to the disruption of the actin cytoskeleton. Activation of the ...
mitogen-activated protein kinase; EGF, epidermal growth factor; LTR, long terminal repeat The ras, i...
We show that expression of the microtubule depolymerizing kinesin KIF2C is induced by transformation...
Receptor for hyaluronan mediated motility (RHAMM, encoded by HMMR) may be a cell-surface receptor fo...
Oncogenic Ras genes are activated by point mutation in about 30% of human tumours, being one of the ...
AbstractIncreasing evidence suggests that activated erk regulates cell functions, at least in part, ...
Increasing evidence suggests that activated erk regulates cell functions, at least in part, by mecha...
An oncogenic form of RHAMM (receptor for hyaluronan-mediated motility, mouse, amino acids 163-794 te...
grantor: University of TorontoWe assessed CD44, RHAMM, erk, and ras expression in human br...
We have previously reported that non-muscle myosin II (NMMII) and myosin light chain kinase (MLCK) a...
AIM: Most neoplastic cells express diminished levels of tropomyosin (TM) family of actin-binding pro...
Activating mutations in the RasGTPases are the most common oncogenic lesions in human cancer. Simila...
Activating mutations in the RasGTPases are the most common oncogenic lesions in human cancer. Simila...
Ras is a key regulator of the MAP kinase-signaling cascade and may cause morphologic change of Ras-t...
This article is hosted on a website external to the CBCRA Open Access Archive. Selecting “View/Open...
Oncogenic transformation often leads to the disruption of the actin cytoskeleton. Activation of the ...
mitogen-activated protein kinase; EGF, epidermal growth factor; LTR, long terminal repeat The ras, i...
We show that expression of the microtubule depolymerizing kinesin KIF2C is induced by transformation...
Receptor for hyaluronan mediated motility (RHAMM, encoded by HMMR) may be a cell-surface receptor fo...
Oncogenic Ras genes are activated by point mutation in about 30% of human tumours, being one of the ...